Following the Appointment of Dr. Doug Buerger as COO, Jiuzi Holdings, Inc.’s Board Endorses Crypto Asset Investment Policy Allowing Up to $1 Billion Deployment
HANGZHOU, China, Sept. 24, 2025 /PRNewswire/ — Jiuzi Holdings, Inc. (NASDAQ: JZXN; the “Company”) today announced that its Board of Directors has... Read more.
From Newfoundland to Ontario: TxtSquad Expands Canadian Innovation in Healthcare
Built in Newfoundland, proven in partnership with NL Health Services, TxtSquad brings its Canadian-built patient engagement platform to Ontario — strengthening... Read more.
Registrar Corp and Denver Health Announce Adverse Event Protection Program to Safeguard Consumers and Cosmetics Brands
Over 26,000 Cosmetics Serious Adverse Events Reported to FDA in 2024 HAMPTON, Va., Sept. 24, 2025 /PRNewswire/ — Registrar Corp, the global leader in... Read more.
RBC urges Canadians to protect their digital persona in a new era of cyber risk
TORONTO, Sept. 24, 2025 /CNW/ – Artificial Intelligence (AI) is a useful tool for everyday productivity, but it has also become a weapon for cyber criminals... Read more.
PayPal Announces a Multi-Year Relationship for U.S. Buy Now, Pay Later Receivables with Funds Managed by Blue Owl Capital
Blue Owl managed funds to purchase approximately $7 billion of PayPal “Pay in 4” loans originated in the U.S. over the next two years SAN JOSE,... Read more.
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ — SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data... Read more.
Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
New agreement brings advanced DDoS protection, traffic analysis, and Zero Trust controls to UK service providers LONDON, Sept. 24, 2025 /PRNewswire/ — Today,... Read more.
Marengo to Present a Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Clinical Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoint Blockade
Data to be presented from the STARt-001 trial demonstrating invikafusp’s single-agent anti-tumor activity in diverse, large cancer indications CAMBRIDGE, Mass.,... Read more.
New report finds chronic and mental health conditions are exacerbated by extreme weather events
Employees living with one or more chronic health conditions were two times more likely to report physical and mental health impacts TORONTO, Sept. 24, 2025 /CNW/... Read more.
Slideshare Rebrands to Inspire a New Era of Knowledge Sharing
Presentation-sharing platform from Scribd, Inc. is company’s third brand rebuilt by Mother Design, with identity overhaul, fresh vision, and tools SAN FRANCISCO,... Read more.